Priority Review Voucher Fee Rises 4.6% For Fiscal 2018
As of Oct. 1, the fee for rare pediatric disease and tropical disease priority review vouchers will be $2.83m; the increase follows a slight decline in FY 2017.
You may also be interested in...
Additional fee will be less than traditional PDUFA application fee in FY 2019, meaning voucher redemptions will cost less than double a typical application review.
US FDA completes updates for biosimilars and novel drug fee schedules as PDUFA VI is set to begin.
US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.